Jeremy Krebs

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women

Jeremy Krebs, Lucy M. Browning, Nathaniel McLean et al. · International Journal of Obesity · 2006 · 218 citations

Obesity, Metabolic Syndrome, Nutrition +11

Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial

Brian Corley, Richard Carroll, Rosemary M. Hall et al. · Diabetic Medicine · 2018 · 207 citations

The impact of long chain <i>n</i> ‐3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype

Lucy M. Browning, Jeremy Krebs, Carmel Moore et al. · Diabetes Obesity and Metabolism · 2006 · 158 citations